New radiation technique tested for aggressive brain cancer
NCT ID NCT01507506
First seen Apr 17, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This phase 3 trial tested two types of radiation therapy for glioblastoma, a fast-growing brain tumor. One group received standard 3D radiation, while the other got a more precise intensity-modulated radiation guided by MRI scans. Both groups also took the chemotherapy drug temozolomide. The study aimed to see if the newer radiation method could help patients live longer. However, the trial was stopped early, so we don't have full results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP HM - Hôpital La Timone
Marseille, 13385, France
-
CHU de Strasbourg
Strasbourg, 67065, France
-
Centre Georges François Leclerc
Dijon, 21000, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Marie Curie
Valence, 26953, France
-
Centre Paul Strauss
Strasbourg, 67065, France
-
Centre Val d'Aurelle
Montpellier, 34298, France
-
Clinique Claude Bernard
Albi, 81000, France
-
Hospices Civils de Lyon (Hôpital Lyon Sud/Hôpital P. Wertheimer)
Lyon, 69002, France
-
Institut Claudius REGAUD
Toulouse, 31052, France
-
Institut de Cancerologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42271, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Temozolomide (chemotherapy) and radiotherapy (radiation)
What this could lead to
If successful, this could show that a more precise radiation technique improves survival for people with glioblastoma.
What could go wrong
The trial was terminated early, so results are limited. It is unclear if the experimental approach is better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.